BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 2 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q3 2023. The put-call ratio across all filers is - and the average weighting 6.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $164,521,000 | -15.1% | 1,129,100 | -30.9% | 3.52% | +15.8% |
Q1 2022 | $193,862,000 | -14.0% | 1,635,000 | 0.0% | 3.04% | +5.5% |
Q4 2021 | $225,319,000 | +22.4% | 1,635,000 | +23.4% | 2.88% | +18.6% |
Q3 2021 | $184,056,000 | -4.8% | 1,325,000 | -33.4% | 2.43% | -6.5% |
Q2 2021 | $193,267,000 | +40.3% | 1,990,797 | -1.2% | 2.60% | +27.2% |
Q1 2021 | $137,725,000 | -9.9% | 2,015,000 | +13.0% | 2.04% | -12.9% |
Q4 2020 | $152,886,000 | +31.8% | 1,783,761 | 0.0% | 2.34% | +3.3% |
Q3 2020 | $115,962,000 | -11.1% | 1,783,761 | 0.0% | 2.27% | -19.9% |
Q2 2020 | $130,411,000 | +114.8% | 1,783,761 | 0.0% | 2.84% | +44.2% |
Q1 2020 | $60,701,000 | -31.8% | 1,783,761 | +9.2% | 1.97% | -21.6% |
Q4 2019 | $88,955,000 | +30.5% | 1,634,000 | 0.0% | 2.51% | +11.3% |
Q3 2019 | $68,170,000 | +89.2% | 1,634,000 | +98.5% | 2.25% | +105.5% |
Q2 2019 | $36,039,000 | +42.0% | 823,000 | +66.9% | 1.10% | +25.5% |
Q1 2019 | $25,375,000 | +39.2% | 493,000 | 0.0% | 0.87% | +8.2% |
Q4 2018 | $18,231,000 | +65.1% | 493,000 | +67.7% | 0.81% | +99.3% |
Q3 2018 | $11,040,000 | +10.0% | 294,000 | +15.7% | 0.40% | -2.9% |
Q2 2018 | $10,038,000 | +12.6% | 254,000 | -26.6% | 0.42% | 0.0% |
Q1 2018 | $8,913,000 | +36.5% | 346,000 | +43.0% | 0.42% | +22.6% |
Q4 2017 | $6,529,000 | +228.1% | 242,000 | +354.5% | 0.34% | +200.9% |
Q3 2017 | $1,990,000 | +49.5% | 53,240 | 0.0% | 0.11% | +36.1% |
Q2 2017 | $1,331,000 | – | 53,240 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Knoll Capital Management, LLC | 490,422 | $12,755,876 | 13.24% |
FNY Investment Advisers, LLC | 30 | $0 | 0.00% |